tetano
Editor, Senior Moderator
Sci Rep
. 2020 Dec 11;10(1):21805.
doi: 10.1038/s41598-020-77791-8.
Impact of comorbid asthma on severity of coronavirus disease (COVID-19)
Sang Chul Lee[SUP] 1 [/SUP], Kang Ju Son[SUP] 2 3 [/SUP], Chang Hoon Han[SUP] 1 [/SUP], Ji Ye Jung[SUP] 4 [/SUP], Seon Cheol Park[SUP] 5 [/SUP]
Affiliations
Abstract
The severity of the coronavirus disease (COVID-19) is associated with various comorbidities. However, no studies have yet demonstrated the potential risk of respiratory failure and mortality in COVID-19 patients with pre-existing asthma. We selected 7272 adult COVID-19 patients from the Korean Health Insurance Review and Assessment COVID-19 database for this nationwide retrospective cohort study. Among these, 686 patients with asthma were assessed by their severities and evaluated by the clinical outcome of COVID-19 compared to patients without asthma. Of 7272 adult COVID-19 patients, 686 with asthma and 6586 without asthma were compared. Asthma was not a significant risk factor for respiratory failure or mortality among all COVID-19 patients (odds ratio [OR] = 0.99, P = 0.997 and OR = 1.06, P = 0.759) after adjusting for age, sex, and the Charlson comorbidity score. However, a history of acute exacerbation (OR = 2.63, P = 0.043) was significant risk factors for death among COVID-19 patients with asthma. Asthma is not a risk factor for poor prognosis of COVID-19. However, asthma patients who had any experience of acute exacerbation in the previous year before COVID-19 showed higher COVID-19-related mortality, especially in case of old age and male sex.
. 2020 Dec 11;10(1):21805.
doi: 10.1038/s41598-020-77791-8.
Impact of comorbid asthma on severity of coronavirus disease (COVID-19)
Sang Chul Lee[SUP] 1 [/SUP], Kang Ju Son[SUP] 2 3 [/SUP], Chang Hoon Han[SUP] 1 [/SUP], Ji Ye Jung[SUP] 4 [/SUP], Seon Cheol Park[SUP] 5 [/SUP]
Affiliations
- PMID: 33311519
- PMCID: PMC7733453
- DOI: 10.1038/s41598-020-77791-8
Abstract
The severity of the coronavirus disease (COVID-19) is associated with various comorbidities. However, no studies have yet demonstrated the potential risk of respiratory failure and mortality in COVID-19 patients with pre-existing asthma. We selected 7272 adult COVID-19 patients from the Korean Health Insurance Review and Assessment COVID-19 database for this nationwide retrospective cohort study. Among these, 686 patients with asthma were assessed by their severities and evaluated by the clinical outcome of COVID-19 compared to patients without asthma. Of 7272 adult COVID-19 patients, 686 with asthma and 6586 without asthma were compared. Asthma was not a significant risk factor for respiratory failure or mortality among all COVID-19 patients (odds ratio [OR] = 0.99, P = 0.997 and OR = 1.06, P = 0.759) after adjusting for age, sex, and the Charlson comorbidity score. However, a history of acute exacerbation (OR = 2.63, P = 0.043) was significant risk factors for death among COVID-19 patients with asthma. Asthma is not a risk factor for poor prognosis of COVID-19. However, asthma patients who had any experience of acute exacerbation in the previous year before COVID-19 showed higher COVID-19-related mortality, especially in case of old age and male sex.